Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals with Sepsis: A Systematic Review and Meta-Analysis

被引:8
|
作者
Zhang, Qiang [1 ]
Qi, Zhijiang [1 ]
Bo-Liu [1 ]
Li, Chun-Sheng [1 ]
机构
[1] Capital Med Univ, Beijing Chao Yang Hosp, Beijing Key Lab Cardiopulm Cerebral Resuscitat, Beijing 100020, Peoples R China
关键词
INDUCED IMMUNOSUPPRESSION; ANTI-PD-L1; ANTIBODY; ADVANCED CANCER; EXPRESSION; PD-1; MORTALITY; IMMUNOTHERAPY; INCREASES; INFECTION; DISEASES;
D O I
10.1155/2018/1969474
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Object. To investigate effects of programmed cell death-1 (PD-1) related blockade in sepsis animals. Methods. Two reviewers independently searched electronic databases including PubMed, EMBASE, and the Cochrane Library up to February 2017. Strict literature retrieval and data extraction were performed to extract relevant data. Data analysis was conducted using RevMan 5.3 software and Stata version 12.0. And relative risks (RRs) for survival rate were calculated. A fixed-effect model was selected to pool and a forest plot was used to display RRs. Results. Four studies involving 394 animals were finally included. Nine control groups are used to pool. A fixed-effect model was applied to estimate a pooled RR of 2.19 (95% CI: 1.74-2.76), indicating that PD-1 related blockade increased survival rate in sepsis animals. Conclusion. We concluded that PD-1 related blockade can improve survival of animals with sepsis. But robust standardized clinical experiments for sepsis patients are highly desirable.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy
    Xiao, Yuchen
    Zhu, Tianchuan
    Zeng, Qi
    Tan, Qingqin
    Jiang, Guanmin
    Huang, Xi
    ACTA BIOMATERIALIA, 2023, 157 : 451 - 466
  • [42] Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction
    Kawashita, Seiji
    Aoyagi, Koichi
    Yamanaka, Hiroshi
    Hantani, Rie
    Naruoka, Shiori
    Tanimoto, Atsuo
    Hori, Yuji
    Toyonaga, Yukiyo
    Fukushima, Kyoko
    Miyazaki, Susumu
    Hantani, Yoshiji
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2019, 29 (17) : 2464 - 2467
  • [43] Incidence and risk of colitis with programmed death-1 versus programmed death-ligand 1 inhibitors for the treatment of cancer.
    Miyashita, Hirotaka
    Mikami, Takahisa
    Satoi, Sera
    Cruz, Christina
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Chen, Daniel S.
    Irving, Bryan A.
    Hodi, F. Stephen
    CLINICAL CANCER RESEARCH, 2012, 18 (24) : 6580 - 6587
  • [45] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma (vol 27, pg 384, 2015)
    Cheah, C. Y.
    Fowler, N. H.
    Neelapu, S. S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (06) : 568 - 568
  • [46] Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction
    Wu, Yizhe
    Zhang, Yu
    Guo, Yu
    Pan, Zhichao
    Zhong, Shichun
    Jin, Xinxin
    Zhuang, Weihao
    Chen, Sikang
    Gao, Jian
    Huang, Wenhai
    Dong, Xiaowu
    Che, Jinxin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223
  • [47] Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
    Niedzwiedzka-Rystwej, Paulina
    Majchrzak, Adam
    Aksak-Was, Bogusz
    Serwin, Karol
    Czajkowski, Zenon
    Grywalska, Ewelina
    Korona-Glowniak, Izabela
    Rolinski, Jacek
    Parczewski, Milosz
    CELLS, 2022, 11 (12)
  • [48] Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis
    Jun-shuai Xue
    Hui Liu
    Guang-Xiao Meng
    Zi-Niu Ding
    Lun-Jie Yan
    Sheng-Yu Yao
    Hai-Chao Li
    Zhao-Ru Dong
    Zhi-Qiang Chen
    Jian-Guo Hong
    Tao Li
    Cancer Immunology, Immunotherapy, 2022, 71 : 1633 - 1644
  • [49] Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis
    Xue, Jun-Shuai
    Liu, Hui
    Meng, Guang-Xiao
    Ding, Zi-Niu
    Yan, Lun-Jie
    Yao, Sheng-Yu
    Li, Hai-Chao
    Dong, Zhao-Ru
    Chen, Zhi-Qiang
    Hong, Jian-Guo
    Li, Tao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1633 - 1644
  • [50] Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors A protocol for systematic review and meta-analysis
    Li, Honglin
    Han, Deting
    Feng, Xiaoteng
    Yu, Wenjun
    Xu, Tongtong
    Ma, Tao
    Song, Lucheng
    MEDICINE, 2020, 99 (32) : E21613